SUTRO BIOPHARMA, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SUTRO BIOPHARMA, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $11.31M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $12.28M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $10.53M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $8.63M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $19.09M | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | $7.84M | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | $5.70M | Mar 16, 2020 |
| FY2019 | Mar 31, 2018 | $5.79M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $4.04M | Apr 1, 2019 |
| FY2018 | Sep 30, 2017 | $17.50M | Apr 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.48M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $62.04M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $153.73M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $67.77M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $61.88M | Mar 25, 2024 |
| FY2020 | Dec 31, 2020 | $8.28M | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | $17.82M | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | $9.47M | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | $7.15M | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | $11.31M | Mar 18, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($191.09M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($227.46M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($106.79M) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | ($119.20M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($105.54M) | Mar 25, 2024 |
| FY2020 | Dec 31, 2020 | ($59.54M) | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | $17.14M | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | $29.87M | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | ($19.60M) | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | ($14.79M) | Mar 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($158.37M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($238.45M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($89.28M) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | ($128.94M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($98.52M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | ($71.06M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($55.47M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($37.22M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | ($19.27M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $1.36M | Apr 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.42M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $252.04M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $180.43M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $137.17M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $104.40M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $76.96M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $65.61M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $54.26M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | $54.64M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $43.55M | Apr 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($177.23M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($191.54M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($111.62M) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $3.55M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($81.68M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | ($67.80M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($65.02M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $12.68M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | ($37.07M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($13.15M) | Apr 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.56M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $3.32M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $4.39M | Apr 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.83M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $387.21M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $470.74M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $406.94M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $341.41M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $394.11M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $156.37M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $223.14M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $40.77M | Apr 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $306.28M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $342.61M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $321.09M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $189.90M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $88.84M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $62.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $58.58M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $91.60M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $47.27M | Apr 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($132.45M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $44.60M | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $149.65M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | $217.05M | Mar 13, 2025 |
| FY2024 | Dec 31, 2021 | $252.56M | Mar 13, 2025 |
| FY2023 | Dec 31, 2020 | $332.05M | Mar 25, 2024 |
| FY2022 | Dec 31, 2019 | $97.79M | Mar 30, 2023 |
| FY2021 | Dec 31, 2018 | $131.54M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | ($109.00M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2016 | ($90.90M) | Mar 16, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($977.96M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($786.87M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($559.41M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($452.62M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($333.41M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($227.87M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($195.75M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($150.33M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($115.01M) | Apr 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.13M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $190.30M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $69.27M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $47.25M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $30.41M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $206.15M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $4.96M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $125.30M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | $22.02M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $11.59M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.06M | Mar 25, 2024 |
| FY2023 | Dec 31, 2022 | $16.27M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $25.11M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $24.55M | Feb 28, 2022 |
| FY2018 | Dec 31, 2018 | $14.72M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (22) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (29) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Mar 25, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (22) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (29) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Mar 25, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.58M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 8.31M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 61.01M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 57.50M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 46.33M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 45.75M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 23.10M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 22.85M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 465,330 | Apr 1, 2019 |